GlassScriptPhysician profile
Richard T Milazzo, JR.
NPI 1487605150
$2,563.47
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $593 · 2021: $667 · 2022: $436 · 2023: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $332.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $435.11 | 2019-2023 | Otezla, Repatha |
| Novo Nordisk INC | $317.62 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $222.83 | 2019-2022 | |
| Abbvie INC. | $193.14 | 2021-2023 | |
| Glaxosmithkline, LLC. | $144.08 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $132.22 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.15 | 2019-2022 | |
| Astellas Pharma US INC | $123.96 | 2019-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $123.16 | 2019-2022 | |
| Abbott Laboratories | $101.31 | 2022-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $61.82 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.46 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.54 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $53.09 | 2019-2022 | |
| Exact Sciences Corporation | $48.93 | 2023 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $48.85 | 2020 | |
| Daiichi Sankyo INC. | $44.37 | 2020-2022 | |
| Pfizer INC. | $38.24 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $35.53 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $28.20 | 2019-2020 | |
| Mannkind Corporation | $24.21 | 2020 | |
| Allergan, INC. | $22.86 | 2020 | |
| Esperion Therapeutics, INC. | $22.54 | 2021 | |
| Mylan Specialty L.P. | $20.23 | 2022 | |
| Genzyme Corporation | $17.02 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.37 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.59 | 2019 | |
| Pacira Therapeutics, INC. | $12.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.18 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Milazzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.